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Abstract
Background: During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic
influenza A (H1N1) vaccine CelvapanH (Baxter) was used in Austria. CelvapanH is adjuvant-free and was the only such
vaccine at that time in Europe. The objective of this observational, non-interventional, prospective single-center study was
to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals.
Methods and Findings: A standard hemagglutination inhibition (HAI) assay was used for evaluation of the seroconversion
rate and seroprotection against the pandemic H1N1 strain. In addition, H1N1-specific IgG antibodies were measured using a
recently developed ELISA and compared with the HAI results. Tolerability of vaccination was evaluated up to one month
after the second dose. A total of 79 HIV-infected adults with an indication for H1N1 vaccination were evaluated. At baseline,
55 of the 79 participants had an HAI titer $1:40 and two patients showed a positive IgG ELISA. The seroconversion rate was
31% after the first vaccination, increasing to 41% after the second; the corresponding seroprotection rates were 92% and
83% respectively. ELISA IgG levels were positive in 25% after the first vaccination and in 37% after the second. Among the
participants with baseline HAI titers ,1:40, 63% seroconverted. Young age was clearly associated with lower HAI titers at
baseline and with higher seroconversion rates, whereas none of the seven patients .60 years of age had a baseline HAI titer
,1:40 or seroconverted after vaccination. The vaccine was well tolerated.
Conclusion: The non-adjuvanted pandemic influenza A (H1N1) vaccine was well tolerated and induced a measurable
immune response in a sample of HIV-infected individuals.
Citation: Lagler H, Grabmeier-Pfistershammer K, Touzeau-Ro ¨mer V, Tobudic S, Ramharter M, et al. (2012) Immunogenicity and Tolerability after Two Doses of
Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals. PLoS ONE 7(5): e36773. doi:10.1371/journal.pone.0036773
Editor: John E. Tavis, Saint Louis University, United States of America
Received November 27, 2011; Accepted April 5, 2012; Published May 21, 2012
Copyright:  2012 Lagler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: heinz.burgmann@meduniwien.ac.at
Introduction
A new swine-origin, triple-reassortant influenza A (H1N1) virus
that emerged in Mexico in late March 2009 began to spread
rapidly through human-to-human transmission outside the usual
influenza season [1–3]. On June 11th, 2009, the World Health
Organization raised the influenza pandemic alert to the highest
level (level 6) as human influenza A (H1N1) cases were reported
worldwide in 74 countries [4]. The pandemic virus was
antigenically and genetically unrelated to human seasonal
influenza virus, and former seasonal influenza vaccines appeared
not protective. Reports of severe respiratory failure associated with
this strain, particularly in young persons, forced the rapid
implementation of a vaccine and resulted in development of
several pandemic anti-influenza A H1N1 2009 vaccines to be
distributed around the world [1–3]. In October 2009, in addition
to various adjuvanted pandemic H1N1 vaccines, the European
Medicines Agency (EMA) licensed an inactivated whole-virion,
Vero-cell-derived pandemic H1N1 influenza A/California/07/
2009 vaccine without adjuvant. This vaccine was based on an
earlier H5N1 mock-up vaccine [3]. In Austria, the Federal
Ministry of Health selected this vaccine for use during the national
pandemic vaccination campaign from November 2009 to March
2010 and therefore it was the only available pandemic vaccine in
Austria during the whole of the pandemic period. At this time
international guidelines from the Centers for Disease Control and
Prevention recommended vaccination [5] particularly for immu-
nocompromised individuals, since underlying medical conditions
such as immunosuppression appeared to predispose for infection
with H1N1 [2]. Immunosuppressed patients are at increased risk
of both greater morbidity due to influenza infection [6] and lower
immune response rates to vaccination [7]. During the pandemic it
was therefore recommended that at least all high-risk HIV-positive
individuals and their close contacts should receive pandemic
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or at least to mitigate the severity of illness and impact of the
disease [8].
According to the Committee for Medicinal Products for Human
Use (CHMP) at the EMA [9], the following serological assessments
should be considered in adult subjects aged between 18 and 60
years, and at least one of the assessments should meet the indicated
requirements: (1) 70% of subjects should show seroprotection after
vaccination (hemagglutination inhibition (HAI) antibody titers
$1:40); (2) 40% of subjects should show seroconversion ($4-fold
increase in HAI antibody titer after vaccination and post-
vaccination titers $1:40); (3) the increase in geometric mean titers
(GMTs) after vaccination should be .2.5-fold. For adults .60
years the CHMP requirements are: 60% of subjects achieving
seroprotection, .30% of subjects showing seroconversion or
significant ($4-fold) increase in HAI antibody titers, and a GMT
increase after vaccination .2-fold. An HAI antibody titer of 1:40
is associated with a 50% reduction in risk of illness in a susceptible
adult population [10,11].
It is well established that whole-virion vaccines are more
immunogenic than conventional split-virion vaccines [12–14], and
this particular whole-virion vaccine has shown good immunoge-
nicity in mice [15]. Reports at the beginning of the vaccination
program indicated promising immunogenicity and tolerability in
the healthy population [3]. The objective of our study was to
determine immunogenicity and tolerability after first and second
doses of this unique adjuvant-free pandemic influenza A (H1N1)
vaccine in a population of HIV-infected individuals during the
pandemic because responses to this vaccine were uncertain at that
time.
Methods
Participants
HIV-infected persons of both sexes, willing to be vaccinated,
were recruited between November 2009 and March 2010 at
Vienna General Hospital, Austria, during their routine visits to the
HIV outpatient department. We excluded individuals with known
cases of influenza A (H1N1) infection and previous recipients of
any other new pandemic 2009 influenza A (H1N1) vaccine. Blood
samples for determination of the virus-specific antibody response
were obtained at baseline before vaccination (t0) and after each
vaccination (t1 and t2). Inclusion criteria included HIV serology
confirmed by western blot and PCR, absence of fever (body
temperature #37.5uC), and a fully completed and signed
standardized information sheet that provided information on the
new pandemic vaccine CelvapanH (Baxter, Vienna, Austria) and
recorded the medical history of the individual. Clinical, laboratory,
and HIV-related data were extracted from patients’ charts.
Detailed vaccination histories were also collected. Adverse effects
and influenza-specific symptoms were recorded during indicated
visits or by phone one month after each vaccination.
Vaccine details
The inactivated whole-virion vaccine CelvapanH (Baxter,
Vienna, Austria) [16] was derived from cultured Vero cells and
supplied in multidose vials, each 0.5 ml dose containing 7.5 mgo f
hemagglutinin from influenza A/California/07/2009 (H1N1).
Virions had been inactivated with formaldehyde and UV
irradiation and purified on a sucrose density gradient. The
finished product was a suspension for intramuscular injection
without added adjuvant or preservatives such as antibiotics.
CelvapanH was the only adjuvant-free pandemic H1N1 vaccine
licensed in Europe [3,17] and the only available pandemic 2009
influenza A H1N1 vaccine in Austria during the pandemic of
2009/2010 (=study period). The vaccination schedule consisted
of an injection into the deltoid muscle on days 0 and 21 or later.
Laboratory methods
The immune response to vaccination was assessed using a
standard HAI assay and an H1N1-specific immunoglobulin G
(IgG) ELISA before and after each vaccination, as previously
described [18]. Blood samples collected as part of routine care
were used for the tests, and all sera were continuously stored at
280uC before testing in duplicate by a reference laboratory
(Bonostix GmbH & Co. KG, Kornwestheim, Germany).
The standardized HAI [19] assay employed chicken red blood
cells and influenza A/H1N1pdm virus A/California/7/2009
obtained from the National Institute for Biological Standards
and Control (UK). The following immunogenicity endpoints were
calculated from individual HAI antibody titers: the proportions of
seroprotection (HAI antibody titers $1:40 after vaccination),
seroconversion (HAI antibody titer prevaccination ,1:10 and
postvaccination $1:40 or prevaccination $1.10 and a four fold
increase or more postvaccination), and the ratio of GM of HAI
antibody titers before and after vaccination [9].
In addition, specific IgG antibodies to pandemic H1N1 were
determined using a commercial ELISA (Pandemic New Influenza
A ELISA IgG/IgA Testkit, Genzyme Virotech GmbH, Ru ¨ssel-
sheim, Germany). According to the manufacturer’s instructions,
the presence of H1N1-specific antibodies is indicated by IgG
antibodies .11units (U). Levels between 9 U and 11 U are
counted as negative (below seroprotection limit). The described
IgG test sensitivity and specificity were 95.7% and 95.0%
respectively.
Statistical analysis
Data of all participants (intention-to-treat population) were
recorded on predesigned paper forms and checked manually
before entry into a purpose-built computer database for analysis
using a commercial software package (JMP 5.0, SAS, NC).
Descriptive statistics were computed for patient demographics,
seroconversion rates, and mean antibody titers. Differences in
seroconversion rates were assessed using the x
2 test or Student’s t-
test as appropriate. The sample size of this study was estimated to
detect a 60% difference in response rates between groups
(b=0.08) assuming 40% seroconversion and allowing for a 10%
loss to follow up (n=79). The significance level was set at a=0.05
and no formal correction for multiple testing was performed.
Ethical approval and compliance with national guidelines
We obtained formal ethical approval from the local ethics
committee at the Medical University of Vienna (Austria). The
committee waived the need for informed consent from individual
participants of the study because blood collected for routine
investigations was used for testing immune responses to vaccina-
tion and therefore no additional blood sampling was necessary.
The study was classified as service evaluation.
Guidance from the Austrian Federal Ministry of Health was
that all HIV-infected individuals should be considered at high risk
for a severe course of 2009 pandemic influenza A (H1N1) and
should therefore receive the vaccine CelvapanH (Baxter, Vienna,
Austria) as one of the initial target groups and as a part of
outpatient care. All data were collected and handled in accordance
with the standards of Good Clinical Practice and Austrian
regulatory requirements. The study was conducted in accordance
with the principles of the Declaration of Helsinki.
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Seventy-nine HIV-infected persons (19 women; median age 40
years, 95% CI 37–42 years; 7 individuals .60 years) were
vaccinated, evaluated, and provided blood samples for serological
analysis. Overall, 72 study participants (91%) completed the
schedule of two vaccinations, seven people were vaccinated only
once. Table 1 shows the demographic, clinical and laboratory
characteristics of the study population. None had received high-
dose immunosuppressive regimens, four women were pregnant at
the time of vaccination. Median time intervals were as follows:
between the first and second vaccinations 28 days (95% CI 26–31),
between first vaccination and second blood sample 28 days (95%
CI 27–32), between second vaccination and third blood sample 56
days (95% CI 51–70). Before vaccination, all 79 blood samples
were available for serological testing. After the first vaccination 71
blood samples of 79 patients were available, and after the second
vaccination 70 blood samples of 72 patients were available.
At baseline 55 (70%) of the participants (n=79) already had
HAI titers $1:40 (.1:40, n=24, 30%). Among those #60 years,
48 (67%) of 72 had HAI titers $1:40 (.1:40, n=19, 26%). In
contrast, only two (3%) of 78 baseline serum samples were positive
for H1N1 virus-specific IgG in the ELISA (Table 2, Figures 1 and
2). Following the first vaccination 65 (92%) of 71 serum samples
and following the second vaccination 58 (83%) of 70 serum
samples had an HAI titer $1:40 (Table 2, Figures 1 and 2).
Seroconversion was found in 22 (31%) of 71 patients after the first
vaccination and increased to 29 (41%) of 70 patients after the
second vaccination.
Before vaccination the overall median HAI titer was 1:40 (IQR
1:20–1:80), increasing to 1:80 (IQR 1:40–1:160) after the first
vaccination but not increasing further after the second dose. The
median IgG ELISA values were 5.3 U (IQR 3.4–6.8) at baseline,
increasing to 8 U (IQR 5.6–11) after the first vaccination and
9.6 U (IQR 6.3–13.1) after the second; both these were below the
seroprotection limit and therefore counted as negative.
For individuals who seroconverted in the HAI assay the median
titer after the second vaccination was 1:160 (IQR 1:80–1:160)
compared with 1:40 (IQR 1:20–1:80) for nonconverters. ELISA
testing, however, showed seropositivity in 18 of 72 (25%) patients
after the first vaccination and in 26 of 70 (37%) after the second
(Figure 1).
The GMT measured by HAI assay was 76 after the first
vaccination and 70 after the second dose (Table 2). The
corresponding GMT ratios to baseline were 1.9 and 1.7
respectively. In the seroconverter group the GMT was 103 after
the first vaccination and 152 after the second (corresponding
GMT ratios 4.3 and 6.4). For nonconverters the GMT was 71
after the first vaccination and 56 after the second (corresponding
GMT ratios to baseline 1.3 and 0.8). Among the 19 of 72
participants with baseline HAI antibody titers ,1:40, at least 79%
(n=15) developed protective antibodies and 63% (n=12)
Table 1. All included HIV-positive individuals (n=79) and the response to first intramuscular dose of the novel inactivated, non-
adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine detected by HAI and H1N1-specific IgG serology in 71 available
blood samples.
All included patients Available blood samples after first vaccination n=71
HAI IgG ELISA
Seroconverters Nonseroconverters Seropositivity Seronegativity
N (n, %) 79 22 (31%) 49 (69%) 17 (24%) 54 (76%)
Sex, female (n, %) 19 (24%) 8 (50%) 8 (50%) 4 (27%) 11 (73%)
Age (years)
a 40 (37–42) 34 (29–38) 42 (39–45) 37 (32–42) 40 (37–43)
HAI titer $1:40 before
vaccination (n, %)
b
55 (70%; 59–79%) 10 (21%; 12–35%) 37 (79%; 65–88%) 13 (27%; 17–41%) 35 (73%; 59–83%)
age .60 years (n, %)
b 7 (9%; 4–17%) 0 (0%) 5 (100%; 57–100%) 0 (0%) 5 (100%; 57–100%)
age #60 years (n, %)
b 72 (91%; 83–96%) 22 (33%; 23–45%) 44 (67%; 55–77%) 17 (26%; 17–37%) 49 (74%; 63–83%)
AIDS criteria (CDC C3) (n, %)
b 11 (14%; 8–23%) 3 (30%; 11–60%) 7 (70%; 40–89%) 2 (22%; 6–55%) 7 (78%; 45–94%)
Duration of HIV infection
(months)
a
75 (61–89) 63 (38–89) 74 (57–91) 75 (46–104) 68 (52–84)
HAART (n, %)
b 69 (87%; 78–93%) 19 (31%; 21–44%) 42 (69%; 56–79%) 16 (26%; 17–38%) 45 (74%; 62–83%)
HIV RNA PCR load (log10copies/
ml)
a
4.2 (3.6–4.4) 3.7 (,1.7–4.1) 4.3 (3.3–4.6) 3.7 (,1.7–4.1) 4.3 (3.4–4.5)
below limit of quantification (n, %)
b 48 (61%; 50–71%) 14 (33%; 20–47%) 29 (67%; 53–80%) 10 (23%; 13–38%) 33 (77%; 62–87%)
50–1000 (n, %)
b 12 (15%; 8–23%) 3 (30%; 19–73%) 7 (70%; 27–81%) 5 (50%; 19–73%) 5 (50%; 19–73%)
.1000 (n, %)
b 19 (24%; 15–33) 4 (22%; 10–47%) 14 (78%; 52–90%) 2 (11%; 3–34%) 16 (89%; 66–97%)
cd4 cell count (cells/ml)
a 502 (449–556) 483 (394–572) 489 (430–549) 439 (340–539) 508 (453–564)
,200 (n, %)
b 3 (4%; 1–11%) 1 (50%; 9–91%) 1 (50%; 9–91%) 1 (50%; 9–91%) 1 (50%; 9–91%)
200–350 (n, %)
b 18 (23%; 15–33%) 5 (29%; 13–53%) 12 (71%; 47–87%) 4 (25%; 10–49%) 12 (75%; 51–90%)
.350 (n, %)
b 58 (73%; 63–82%) 17 (33%; 22–46%) 35 (67%; 54–78%) 13 (25%; 15–38%) 40 (75%; 62–85%)
Nadir cd4 cell count (nadir cell/ml)
a 243 (203–282) 278 (201–355) 241 (190–294) 207 (120–295) 268 (219–317)
Duration of nadir cd4 cell count
(months)
a
40 (30–51) 25 (4–45) 47 (33–60) 46 (22–69) 39 (25–52)
doi:10.1371/journal.pone.0036773.t001
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with an HAI baseline titer ,1:20 (n=7), 86% (n=6) developed
protective HAI antibody titers and the same proportion serocon-
verted after the second dose (Figure 3).
In the HAI assay, seroconverters were younger than non-
converters, particularly those who converted after the first
vaccination (34 vs. 42 years; p=0.006) and had an HAI baseline
titer ,1:40 (21% vs. 79%; p=0.015). Furthermore, after the
second vaccine dose the group #60 years seroconverted in the
HAI assay more frequently (45% vs. 55%; p=0.038) than the
older age group .60 years. Detailed immunogenicity and
statistical results in the different subgroups after the first dose of
vaccine are summarized in Table 1 and after the second dose in
Table 3.
Pregnancy (n=4) and comorbidity such as hepatitis C (n=7) or
diabetes (n=3) at the time of vaccination did not correlate with the
three measured immunogenicity parameters. A subgroup of 47
patients were systematically asked about seasonal influenza
vaccination received during the previous three years or other
vaccinations in the past 12 months. The immunization rate was in
general low (2009/10 n=9; 2008/09 n=3; 2007/08 n=4; other
vaccinations, n=2) and there was no correlation with HAI titer at
baseline or the three immunogenicity parameters (data not shown).
Local tolerability was excellent. A painful induration at the
injection site for one day was reported for only one of 151
vaccinations (79 first doses, 72 second doses). Systemic side effects
were rare. One patient developed generalized pruritus after the
first dose and was not vaccinated again. After the second dose, two
patients developed symptoms of fatigue considered possibly related
to the vaccination by the investigators. The only serious adverse
event necessitating hospital admission was a fatal fulminant
hepatitis induced by isoniazid as part of TB therapy; this event
was considered unrelated to the vaccination. Four patients had
some type of upper respiratory illness with coughing as the main
symptom. Two of them developed coughing and subfebrile body
temperature ,38uC after the first vaccination (one case 1 day after
vaccine, one case 2 weeks after vaccine). The other two patients
developed coughing and fever .38uC after the second vaccination
(one case 1 day after vaccine, one case 1 week after vaccine). The
patient with coughing and subfebrile body temperature two weeks
after the first vaccine was seen at our HIV outpatient clinic. His
nasopharyngeal swab tested negative in the diagnostic H1N1-
specific and other influenza A PCR. He improved after a few days
and tolerated the second vaccine well. The other three patients did
not report their symptoms until the next routine contact (second
vaccination or on the phone one month after the second
vaccination). All blood samples collected from these four patients
before and after their upper respiratory illness were retested using
an influenza A and B-specific complement-fixation method and
none showed a significant titer increase. These illnesses were not
influenza A and therefore were not documented as vaccination
failures.
At our HIV outpatient department, which regularly monitors
approximately 1,000 HIV-positive individuals in a period of 6
months, only four pandemic influenza A (H1N1) infections were
noticed during the study period. None of these patients had been
vaccinated and all had typical symptoms such as fever, coughing,
and joint pain without complications.
Figure 1. Comparison of three vaccination outcome parame-
ters. 1) three columns left: HAI seroprotection rate (HAI antibody titers
$1:40); 2) three columns center: IgG* seropositivity rate (IgG*.11 U); 3)
two columns right: HAI seroconversion rate (4-fold increase in HAI
antibody titers to $1:40); at three time points: t0,t 1 and t2.
Abbreviations: HAI, hemagglutination inhibition test; IgG*, pandemic
H1N1-specific immunoglobulin G serology; t0, time before vaccination;
t1, time after first vaccination; t2, time after second vaccination.
doi:10.1371/journal.pone.0036773.g001
Table 2. Serological response, defined by seroprotection
a, seroconversion
b, GMT
c and GMT ratio
c and seropositivity
d in HIV-
positive individuals before and after first and second intramuscular vaccination with the whole-virion, Vero cell-derived,
inactivated, non-adjuvanted pandemic H1N1 influenza vaccine.
Timepoints t0 t1 t2
Available blood samples n=79 n=71 n=70
Seroprotection
a 55 (70%; 95%CI 59–79%) 65 (92%; 95%CI 83–96%) 58 (83%; 95%CI 72–90%)
Geometric mean
c 40 (95%CI 7–237) 76 (95%CI 11–508) 70 (95%CI 6–793)
Geometric mean ratio
c to baseline NA 1.9 (95%CI 0.2–20) 1.7 (95%CI 0.1–23)
Seroconversion
b NA 22 (95%CI 31%; 21–42%) 29 (95%CI 41%; 31–53%)
Seropositive
d 2 (3%; 95%CI 1–9%) 18 (25%; 95%CI 16–35%) 26 (37%; 95%CI 27–49%)
doi:10.1371/journal.pone.0036773.t002
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The main finding of our study is that during the pandemic HIV-
positive individuals showed a limited but clear response to the
unique, inactivated whole-virion, Vero-cell-derived and non-
adjuvanted pandemic H1N1 vaccine.
For a vaccination to be useful, the seroprotection rate should
exceed 70% in adults #60 years of age, according to the CHMP at
the EMA [9]. Surprisingly, 70% of our HIV-positive study
participants (n=55 of 79) already had HAI antibody titers $1:40
before vaccination. Unlike other influenza pandemics, during the
2009/2010 H1N1 pandemic a high percentage of the population,
especially in the older age group, already showed antibody titers
against this virus [20–22]. Similar findings can also be seen in our
study, where all vaccinated HIV-positive individuals older than 60
years (n=7) had protective HAI antibody titers of $1:40, and
even in younger HIV-positive individuals (#60 years), 67% (n=48
of 72) had protective HAI antibody titers of $1:40, among whom
40% (n=19 of 48) had HAI antibody titers .1:40.
However our findings of a high percentage of HAI titers $1:40
before vaccination are in accordance with recent HIV studies in
children (46% [23]) and adults (79.6% [24]). The authors of the
last mentioned study [24], in Italy, discussed several factors for
these high HAI titers. Their patients were vaccinated after the
beginning of the pandemic, thus exposure to or infection with
influenza A (H1N1) could not be excluded. This may be relevant
for our study population in Austria, a country bordering Italy.
Limitations of the HAI method were also considered. Further-
more, the detection of some antibodies cross-reacting with H1N1
in HAI assay may be an additional explanation [25,26]. Although
Figure 2. Reverse cumulative distribution curves. On HAI assay (Panel A) and H1N1 virus-specific IgG serology by ELISA (Panel B) before
vaccination (t0), after the first vaccination (t1) and after the second vaccination (t2). Abbreviations: HAI, hemagglutination inhibition test; IgG,
immunoglobulin G.
doi:10.1371/journal.pone.0036773.g002
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(HAI), GMT ratio (HAI) and seropositivity (IgG* ELISA) after the second vaccination. Abbreviations: HAI, hemagglutination inhibition test;
IgG*, pandemic H1N1-specific IgG, immunoglobulin G serology; t0, time before vaccination; t2, time after second vaccination; SD, standard deviation;
GMT, geometric mean HAI titer.
doi:10.1371/journal.pone.0036773.g003
Table 3. Response of HIV-positive individuals to second intramuscular dose of the inactivated, non-adjuvanted, whole-virion
pandemic influenza A (H1N1) vaccine detected by HAI and H1N1-specific IgG serology in 70 available blood samples.
Available blood samples after second vaccination n=70
HAI IgG ELISA
Seroconverters Nonseroconverters Seropositivity Seronegativity
N (n, %) 29 (41%) 41 (59%) 26 (37%) 44 (63%)
Sex, female (n, %) 6 (37.5%) 10 (62.5%) 6 (40%) 9 (60%)
Age (years)
a 37 (33–42) 42 (38–46) 40 (35–45) 40 (36–44)
HAI titer $1:40 before
vaccination (n, %)
b
17 (33%; 22–47%) 34 (67%; 53–78%) 21 (42%; 29–56%) 29 (58%; 44–71%)
age .60 years (n, %)
b 0 (0%) 6 (100%; 61–100) 2 (33%; 10–70) 4 (67%; 30–90%)
age #60 years (n, %)
b 29 (45%; 34–57%) 35 (55%; 43–66%) 24 (38%; 27–50%) 40 (63%; 50–73%)
AIDS criteria (CDC C3) (n, %)
b 1 (17%; 3–56%) 5 (83%; 44–97%) 2 (29%; 8–64%) 5 (71%; 36–92%)
Duration of HIV infection
(months)
a
67 (44–90) 80 (60–99) 88 (63–112) 66 (47–84)
HAART (n, %)
b 27 (46%; 34–58%) 32 (54%; 42–66%) 25 (40%; 29–53%) 37 (60%; 47–71%)
HIV RNA PCR load (log10copies/
ml)
a
3.6 (,1.7–4.0) 4.4 (3.5–4.7) 3.2 (,1.7–3.6) 4.4 (3.6–4.7)
below limit of quantification (n, %)
b 16 (38%; 25–53%) 26 (62%; 47–75%) 19 (45%; 31–60%) 23 (55%; 40–69%)
50–1000 (n, %)
b 6 (60%; 31–83%) 4 (40%; 17–69%) 5 (45%; 17–69%) 6 (55%; 31–83%)
.1000 (n, %)
b 6 (33%; 18–61%) 12 (67%; 39–82%) 2 (12%; 3–36%) 15 (88%; 63–97%)
cd4 cell count (cells/ml)
a 494 (403–584) 533 (457–609) 510 (415–605) 531 (458–604)
,200 (n, %)
b 2 (67%; 21–94%) 1 (33%; 6–79%) 2 (67%; 21–94%) 1 (33%; 6–79%)
200–350 (n, %)
b 5 (38%; 18–64%) 8 (62%; 35–82%) 4 (33%; 14–61%) 8 (67%; 39–86%)
.350 (n, %)
b 23 (43%; 30–56%) 31 (57%; 44–70%) 20 (36%; 25–50%) 35 (64%; 50–75%)
Nadir cd4 cell count (nadir cell/ml)
a 265 (198–331) 236 (180–292) 209 (141–278) 273 (220–326)
Duration of nadir cd4 cell count
(months)
a
29 (12–46) 49 (35–63) 41 (23–59) 42 (28–56)
Abbreviations: HAI, hemagglutination inhibition test; IgG, immunoglobulin G;
amedian (95% confidence interval),
b(%; 95% confidence interval).
doi:10.1371/journal.pone.0036773.t003
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before H1N1 vaccination and prior seasonal influenza vaccina-
tions as demonstrated recently [26], ultimately the number of
previously vaccinated patients was much higher (.80%), in
contrast with our study (,20%). However, the majority of recent
HIV studies described mainly lower HAI baseline titers [26–28].
Our recently published data on solid organ transplant (SOT)
patients (n=25) also showed high HAI titers: 59% had titers
$1:40 before vaccination (54% of 25 were patients #60 years)
[18].
As a result of the high pre-vaccination HAI titers, we observed a
seroprotection rate of 91% after the first vaccination in the age
group #60 years, which is comparable to or better than results
with adjuvanted and adjuvant-free vaccines in HIV-positive study
populations [24,27–29].
We found overall seroconversion rates of only 31% after the first
vaccination and 41% after the second, barely meeting the licensing
criteria of CHMP: .40% of subjects #60 years of age and .30%
of subjects .60 years [9]. In the age group #60 years the
seroconversion rate improved slightly up to 45% after the second
vaccination, whereas none of the seven patients .60 years
seroconverted. The seroconversion rates in our studied vaccinated
SOT patients were slightly lower: 23% after the first vaccination
and 37% after the second [18]. Although the majority of recent
immunogenicity studies with adjuvanted pandemic H1N1 influ-
enza vaccines in HIV-positive patients show higher seroconversion
rates [30,31,26], some investigations have reported seroconversion
rates similar to those in our study [24]. The elevated HAI titers at
baseline (Table 2) may explain the notably reduced seroconversion
rate; however, the rate was up to 86% in patients with lower HAI
baseline titers. Whole-virion pandemic influenza vaccine is
designed to provide protection to a population naı ¨ve for a novel
influenza virus. This effect is well documented in our study, where
a more robust immune response was observed in persons with low
HAI antibody titers at baseline (Figure 3).
The third licensing criterion, the mean 2.5-fold increase GM of
HAI antibody titers, was not fulfilled; nevertheless, similarly to the
seroconversion rate, there was a negative correlation with baseline
HAI antibody titers and the GMT ratio (Figure 3). Thus, two of
the three criteria were met in our HIV-positive patients #60 years
of age (Table 2). According to CHMP, only one of the three
criteria should be met to satisfy the immunogenicity requirement,
even in immunocompetent persons [9].
Local adverse events are frequent with adjuvanted vaccines,
whereas the non-adjuvanted, Vero-cell-derived H1N1 influenza
vaccine was well tolerated in the HIV-positive adults in our study,
as also shown in healthy adults [32] and children [33]. The whole-
virion adjuvant-free vaccine was designed to provide the optimal
balance between immunogenicity, effectiveness, and tolerability, as
it was considered that reduced tolerability might have a negative
impact on vaccine uptake.
In the present study immunogenicity was measured by HAI
assay and ELISA and the dissimilarity of test results was
remarkable. The high number of individuals with HAI antibody
titers $1:40 (70%) together with the low seropositivity rate (3%)
measured by virus-specific H1N1 IgG ELISA before vaccination is
unusual and argues that the ELISA is poorly sensitive. Both tests
demonstrated immunogenicity of the H1N1 vaccine after two
doses, but it is difficult to compare the two methods. The trend of
dissimilar results in the two tests was also found in our SOT
patients; for example, before vaccination 59% had HAI antibody
titers $1:40 whereas only 18% were seropositive by ELISA [18].
A recent study by Meyer et al. [34] reported that the ELISA had a
predictive value of only 54% for correctly identifying a vaccine
responder. Dikow et al. [35], however, studied the immunogenicity
of an adjuvanted H1N1 vaccine measured by IgG ELISA in
hemodialysis patients and discussed the problem of calibrating
quantitative results in the absence of an international standard.
Nevertheless, because high values for arbitrary ELISA units
correlate with higher quantitative amounts of antibodies, this may
serve as an acceptable surrogate marker for seroconversion and
seroprotection.
Only a few immunogenicity data on non-adjuvanted pandemic
H1N1 vaccines in HIV-positive individuals have been published
recently [28,36,37]. Apart from the lower protective HAI antibody
baseline titers (8.6–25%) before vaccination, however, these three
studies cannot be simply compared with our study. They all used a
single-dose strategy with an egg-based, split-virion pandemic
H1N1 vaccine containing 15 mg of hemagglutinin per vaccine
dose. In our study we used a two-dose strategy with a Vero-cell-
derived, whole-virion vaccine containing only 7.5 mg hemagglu-
tinin per vaccine dose. The serological responses in patients
without pandemic H1N1 protective HAI antibodies appear
comparable to our study.
Our study has several limitations. The number of patients
studied was small, in particular the number of pandemic H1N1-
naı ¨ve individuals. Furthermore, the study was observational and
non-interventional, and we did not recruit a healthy control group
for direct comparison of immune responses in immunocompro-
mised and immunocompetent persons. However, immunogenicity
in healthy immunocompetent persons has been described recently:
after two courses of vaccination the seroconversion rate was 49%
and the cohort fulfilled all three EMA immunogenicity criteria
[32]. The seroconversion rate in healthy individuals would be
expected to be above the overall seroconversion rate of 41%
reached by our HIV-positive patients; however, those individuals
who were HIV-positive H1N1-naı ¨ve before vaccination achieved a
seroconversion rate of 63% after the second dose of vaccine.
A recent study with Vero-cell-derived seasonal influenza vaccine
also demonstrates that higher HAI antibody titers do not correlate
with increased vaccine effectiveness: titers .1:30 provided no
additional benefit of protection [38], as also reported by other
authors [10,39]. For these reasons, differences in titers between the
adjuvanted split vaccine and the whole-virion vaccine should be
interpreted with caution.
In summary, our results have demonstrated that during the
H1N1 pandemic of 2009/2010 use of the well-tolerated pandemic
adjuvant-free influenza A (H1N1) vaccine resulted in a limited
immune response in HIV-positive patients; however, the response
was more powerful in the population naı ¨ve for 2009 H1N1
influenza virus before vaccination. There is a need for additional
efficacy and safety studies using different dosages and interval
strategies and for head-to-head comparison with adjuvanted
vaccines in this risk population.
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